The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Logiclinx Corporation
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Logiclinx Corporation, a non-promoter entity based in the USA, has acquired 26,40,290 equity shares (5.03% of total share capital) in Telogica Ltd through conversion of warrants into equity shares on 31st October 2025 via preferential allotment. The warrant conversion was pre-agreed and not a fresh market purchase. After the conversion, Logiclinx's total holding stands at 1,00,00,000 shares — 15.06% on a fully diluted basis and 10.87% on total equity capital (up from 6.40% before). Telogica's total equity share capital increased from 4,78,35,786 shares to 5,24,76,076 shares as a result of the warrant conversion, while diluted capital stands at 6,63,93,942 shares.
This is a pre-scheduled warrant conversion, not open-market buying, so it does not reflect new investor demand. For shareholders, it means further equity dilution (more shares now outstanding) and a non-promoter foreign entity has now crossed the 10% ownership mark on equity capital, making it a significant institutional holder worth tracking.